Puma Biotechnology | PBYI - Net Income


Puma Biotechnology reported $20.32M in Net Income for its fiscal quarter ending in September of 2024.





Net Income Change Date
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
Amgen USD 2.38B 556M Jun/2026
Biogen USD 97.5M 222M Jun/2026
BioMarin Pharmaceutical USD 44.76M 60.76M Jun/2026
Daiichi Sankyo JPY 68.64B 18B Jun/2026
Exelixis USD 212.05M 1.58M Jun/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
Glaxosmithkline GBP 1.74B 890.94M Mar/2026
Incyte USD 585.6M 282.27M Jun/2026
MacroGenics USD -36.77M 22.62M Mar/2026
Moderna USD -1.34B 517M Mar/2026
Novartis USD 3.26B 108M Jun/2026
Pfizer USD -248M 2.94B Jun/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Takeda JPY 113.2B 137.52B Jun/2026
TG Therapeutics USD 7.78M 12M Jun/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026